MELIOTIC – wsparcie leczenia onkologicznego
From some time now, it is widely accepted that naming human microbiome our second brain is not an exaggeration. We developed Meliotic – preparation that falls into a novel class of oncological supportive treatment. The patient receiving Meliotic after chemotherapy or radiotherapy gets a chance for a significantly faster recovery of the gastrointestinal tract.
Meliotic is not a cure for cancer but it remarkably improves the quality of life of patients who need special attention – ones that suffer from severe side-effects of anti-cancer therapy.
Improves patients life quality by:
- ensuring faster recovery of the gastrointestinal tract
- helping to regrow of commensal bacteria
- balancing the immune system
- aiding digestion and microelements absorption process to regain vital strength.
The history of our research
December 16′ – April 17′
MAPPING GUT MICROBIOME
During the past century, noncommunicable diseases were the greatest reason for human deaths, even if we would compare to infectious diseases. Trillions of commensal bacteria live in the human body and create as a whole the human microbiome. The great part of these microbes are located within the human gut (but not only) and have a significant impact on human health and survivor, including digesting food, activation of a certain class of medicines, producing metabolites like short-chain fatty acids and anti-inflammatory substances, as well as stimulating the immune system.
May 17′ – August 17′
THE EFFECT OF MICROBIOME ON A METABOLISM IN LIFESTYLE DISEASES
Interactions between the microbiota and the host are very complex and play the crucial role not only in basic physiological processes but also in development (and healing!) of a number of chronic diseases: metabolic disorders like obesity and diabetes, gastrointestinal and cardiovascular diseases, mental disorders and even cancer, to name only a few. It is widely accepted now that human genotype and dietary habits aren’t the only factors contributing to the development of metabolic diseases. It is all about the interplay between these two and host microbiome composition. Obesity itself has been proven to be directly associated with gut microbiome dysbiosis resulting in damaged gut epithelial barrier and impaired metabolism overall.
August 17′ – November 17′
THE ROLE OF GUT MICROBIOTA IN RESPONSE TO A DRUG
The oral administration of therapeutic drugs is an easy and preferred route over other administration routes, however, there are certain aspects that need special attention. Bioavailability of oral drugs primarily depends on well-functioning digestive system and microbiota that colonize the digestive system. It has been proved that human microbiome composition plays an important role in drug and xenobiotic metabolism by means of various enzymatic reactions mediated by microbiota produced enzymes.
December 17′ – April 18′
IMPROVED ABSORPTION OF ACTIVE SUBSTANCE vs. IMPROVING THE EFFECTIVENESS OF PHARMACOTHERAPY
Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. The primary goal of clinical pharmacokinetics includes enhancing efficiency and decreasing toxicity of drug therapy.
THE EFFECT OF OUR WORK